Accolade, Inc. (ACCD)
- Previous Close
9.19 - Open
7.87 - Bid 7.87 x 400
- Ask 7.92 x 200
- Day's Range
7.62 - 8.56 - 52 Week Range
6.33 - 15.36 - Volume
1,490,874 - Avg. Volume
625,531 - Market Cap (intraday)
610.746M - Beta (5Y Monthly) 2.08
- PE Ratio (TTM)
-- - EPS (TTM)
-1.62 - Earnings Date Jun 27, 2024 - Jul 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.80
Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions. In addition, the company offers medical consultations that connect patients to qualified condition-specific specialists for adult and pediatric care; and primary care and mental health support solutions. It serves employers who provide employees and their families a single place to turn for their health, healthcare, and benefits needs. The company was incorporated in 2007 and is headquartered in Seattle, Washington.
www.accolade.com--
Full Time Employees
February 29
Fiscal Year Ends
Sector
Industry
Recent News: ACCD
Performance Overview: ACCD
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACCD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACCD
Valuation Measures
Market Cap
610.75M
Enterprise Value
622.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.51
Price/Book (mrq)
1.40
Enterprise Value/Revenue
1.60
Enterprise Value/EBITDA
-6.75
Financial Highlights
Profitability and Income Statement
Profit Margin
-24.09%
Return on Assets (ttm)
-8.41%
Return on Equity (ttm)
-21.71%
Revenue (ttm)
414.29M
Net Income Avi to Common (ttm)
-99.81M
Diluted EPS (ttm)
-1.62
Balance Sheet and Cash Flow
Total Cash (mrq)
237.03M
Total Debt/Equity (mrq)
54.15%
Levered Free Cash Flow (ttm)
14.61M